

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/720,647
		Filing Date	July 17, 2001
		First Named Inventor	Ramachandran Murali
		Group Art Unit	4614 1631
		Examiner Name	Kevin E. Weddington
Sheet 1	of 3	Attorney Docket Number	4040/OL566-USO

RECEIVED
NOV 13 2002
TECH CENTER 1602/2900

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
col	1.	US- 5,597,719	01-28-1997		


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
col	2.	BANNER et al., (1993) Crystal Structure of the Soluble Human 55kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation, <i>Cell</i> , 73:431-445	
	3.	BERTHOLD et al., (1997) Modes of Peptide Binding in G Protein-Coupled Receptors, <i>Neurochemical Res.</i> , 22:1023-1031	
	4.	BÖHM et al., (1993) A Novel Computational Tool for Automated Structure-based Drug Design, <i>J. of Molecular Recognition</i> , 6:131-137	
	5.	BOTEJU et al., (1996) The Use of Topographical Constraints In Receptor Mapping: Investigation of the Topographical Requirements of the Tryptophan 30 Residue for Receptor Binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH ₂ (SNF 9007), a Cholecystokinin (26-33) Analogue That Binds to both CCK-B and δ -Opioid Receptors, <i>J. Med. Chem.</i> , 39:4120-4124	
	6.	CHO et al., (1996) Macromolecular versus small-molecule therapeutics: drug discovery, development and clinical considerations, <i>Tibtech</i> , 14:153-159	
	7.	CONNOLLY et al., (1993) The molecular surface package, <i>J. Mol. Graphics</i> , 11:139-141	
	8.	D'AQUINO et al., (1996) The Magnitude of the Backbone Conformational Entropy Change in Protein Folding, <i>Proteins</i> , 25:143-156	
	9.	DESJARLAIS et al., (1986) Docking Flexible Ligands to Macromolecular Receptors by Molecular Shape, <i>J. Med. Chem.</i> , 29:2149-2153	
	10.	DESJARLAIS et al., (1988) Using Shape Complementarity as an Initial Screen in Designing Ligands for a Receptor Binding Site of Known Three-Dimensional Structure, <i>J. Med. Chem.</i> , 31:722-729	

Examiner Signature	<i>Chapman</i>	Date Considered	3/04/03
--------------------	----------------	-----------------	---------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	09/720,647
Filing Date	July 17, 2001
First Named Inventor	Ramachandran Murali
Group Art Unit	1814 1631
Examiner Name	Kevin E. Weddington
Attorney Docket Number	4040/OL566-USO

RECEIVED
NOV 13 2002
TECH CENTER 1600/200

cm	11.	ECK et al., (1989) The Structure of Tumor Necrosis Factor- α at 2.6 Å Resolution, <i>J. of Biol. Chem.</i> , 264:17595-17605	
	12.	ECK et al., (1992) The Structure of Human Lymphotoxin (Tumor Necrosis Factor- β) at 1.9-Å Resolution, <i>J. of Biol. Chem.</i> , 267:2119-2122	
	13.	ELLIS J., (1997) Allosteric Binding Sites on Muscarinic Receptors, <i>Drug Development Research</i> , 40:193-204	
	14.	GÓMEZ et al., (1995) Thermodynamic Mapping of the Inhibitor Site of the Aspartic Protease Endothiapepsin, <i>J. Mol. Biol.</i> , 252:337-350	
	15.	GOOD et al., (1995) New molecular shape descriptors: Application in database screening, <i>J. of Computer-Aided Molec. Design</i> , 9:1-12	
	16.	GOODSELL et al., (1996) Automated Docking of Flexible Ligands: Applications of AutoDock, <i>J. of Molec. Recognition</i> , 9:1-5	
	17.	GSCHWEND et al., (1996) Molecular Docking Towards Drug Discovery, <i>J. of Mol. Recognition</i> , 9:175-186	
	18.	HANSEN et al., (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill, <i>J. of Immunological Methods</i> , 119:203-210	
	19.	HILSER et al., (1996) Structure-based Calculation of the Equilibrium Folding Pathway of Proteins. Correlation with Hydrogen Exchange Protection Factors, <i>J. Mol. Biol.</i> , 262:756-772	
	20.	IVERSEN et al., (1997) Characterization of the allosteric binding pocket of human liver fructose-1,6-bisphosphatase by protein crystallography and inhibitor activity studies, <i>Protein Science</i> , 6:971-982	
	21.	KLEYWEGT et al., (1994) Detection, Delineation, Measurement and Display of Cavities in Macromolecular Structures, <i>Acta Cryst.</i> , D50:178-185	
	22.	KOLLIAS-BAKER et al., (1997) Agonist-Independent Effect of an Allosteric Enhancer of the A ₁ Adenosine Receptor in CHO Cells Stably Expressing the Recombinant Human A ₁ Receptor, <i>J. of Pharmacology and Exp. Therapeutics</i> , 281:761-768	
	23.	KUNDROT et al., (1991) Designing an Allosterically Locked Phosphofructokinase, <i>Biochemistry</i> , 30:1478-1484	
	24.	KUNTZ I.D., (1992) Structure-Based Strategies for Drug Design and Discovery, <i>Science</i> , 257:1078-1082	
	25.	LADJIMI et al., (1985) Structure-Function Relationship in Allosteric Aspartate Carbamoyltransferase from <i>Escherichia coli</i> II. Involvement of the C-Terminal Region of the Regulatory Chain in Homotropic and Heterotropic Interactions, <i>J. Mol. Biol.</i> , 186:715-724	
	26.	LANGRIDGE et al., (1981) Real-Time Color Graphics in Studies of Molecular Interactions, <i>Science</i> , 211:661-666	
	27.	LI et al., (1997) A computer screening approach to immunoglobulin superfamily structures and interactions: Discovery of small non-peptidic CD4 inhibitors as novel immunotherapeutics, <i>Proc. Natl. Acad. Sci.</i> , 94:73-78	

Examiner
Signature

Chen


Date
Considered

3/04/03

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	09/720,647
Filing Date	July 17, 2001
First Named Inventor	Ramachandran Murali
Group Art Unit	1614 1631
Examiner Name	Kevin E. Weddington
Attorney Docket Number	4040/OL566-USO

28.	OZAITA et al., (1997) Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I ₂ -imidazoline receptors in rat liver, <i>Brit. J. Pharm.</i> , 121:901-912
29.	ROBICHON et al., (1997) A partial agonist model used in the allosteric modulation of the NMDA receptor, <i>Eur. J. Pharmco.</i> , 328:255-263
30.	SHOICHET et al., (1991) Protein Docking and Complementarity, <i>J. Mol. Biol.</i> , 221:327-346
31.	SOBOLEV et al., (1996) Molecular Docking Using Surface Complementarity, <i>Proteins</i> , 25:120-129
32.	STRYNADKA et al., (1996) Molecular docking programs successfully predict the binding of a β -lactamase inhibitory protein to TEM-1 β -lactamase, <i>Nature Structural Biology</i> , 3:233-239
33.	STRYNADKA et al., (1996) A potent new mode of β -lactamase inhibition revealed by the 1.7 Å X-ray crystallographic structure of the TEM-1-BLIP complex, <i>Nat. Struct. Biol.</i> , 3:290-297
34.	TAKASAKI et al., (1997) Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF α binding to its receptor, <i>Nature Biotechnology</i> , 15:1266-1270
35.	TANG et al., (1997) Rational design of allosteric ribozymes, <i>Chemistry & Biol.</i> , 4:453-459
36.	TIJANE et al., (1989) Conformational Modification of muscle phosphofructokinase from <i>Jaculus orientalis</i> upon ligand binding, <i>FEBS Lett.</i> , 245:30-34
37.	XIE et al., (1994) Thermodynamic characterization of an equilibrium folding intermediate of staphylococcal nuclease, <i>Protein Science</i> , 3:2175-2184

Examiner
SignatureDate
Considered

03/04/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.